Addition of polyunsaturated fatty acids to canola oil by fungal conversion

2008 ◽  
Vol 42 (6) ◽  
pp. 514-520 ◽  
Author(s):  
Meidui Dong ◽  
Terry H. Walker
Author(s):  
David Silva ◽  
Maria Paz Villarroel ◽  
Alba L. Roa ◽  
Benita H. Quilodrán

The aim of this work was to evaluate the possibility of using agroindustrial residues as carbon sources for the production of omega-3 polyunsaturated fatty acids by a native Thraustochytrid strain, and analyze the microorganism growth for each substrate. In this study a Chilean strain, Thraustochytrium kinney VAL-B1, was grown in three alternative carbon sources: lupine residue, fermented wine and residual glycerol from biodiesel canola oil for biomass and polyunsaturated fatty acids production. The highest biomass production values were obtained at the fifth day of growth, which were 7.22±0.56 g L-1, 2.72±0.25 g L-1 and 6.54±0.71 g L-1 for fermentations of lupine residue, fermented wine and residual glycerol from biodiesel canola oil, respectively, while the polyunsaturated fatty acids profile showed a docosahexanoic acid percentage of 21.19%, 13.42% and 35.06% in the fermentations of the above mentioned residues. The highest omega 3 fatty acids production (docosahexanoic and eicosapentanoic acid, 2.53±0.36 g L-1 and 0.25±0.03 g L-1, respectively) was obtained in the fermentation of residual glycerol from biodiesel canola oil. With these results, it was concluded that Thraustochytrium kinney VAL-B1 produces more omega 3 fatty acids (docosahexanoic and eicosapentanoic acid) when is fermented in a medium using residual glycerol from biodiesel canola oil as an alternative carbon source, reaching a productivity of 0.50 g L-1 d-1 for docosahexanoic acid. On the other hand, the highest biomass production was obtained in fermentations of lupine residue (7.22 g L-1). For these reasons, it is feasible to employ agroindustrial by-products for polyunsaturated fatty acids production.


2009 ◽  
Vol 128 (4) ◽  
pp. 348-355 ◽  
Author(s):  
M. N. Aslam ◽  
M. N. Nelson ◽  
S. G. Kailis ◽  
K. L. Bayliss ◽  
J. Speijers ◽  
...  

2011 ◽  
Vol 51 (2) ◽  
pp. 191-198 ◽  
Author(s):  
Carlos Alberto Soares da Costa ◽  
Aluana Santana Carlos ◽  
Gabrielle de Paula Lopes Gonzalez ◽  
Rejane Pontes Gaspar Reis ◽  
Mariana dos Santos Ribeiro ◽  
...  

2020 ◽  
Vol 36 (2) ◽  
pp. 95-106
Author(s):  
Agnieszka M. Piróg-Balcerzak ◽  
Anna K. Bażyńska ◽  
Katarzyna Biernacka ◽  
Joanna Brągoszewska ◽  
Lidia Popek ◽  
...  

Objective. Omega–3 polyunsaturated fatty acids (PUFAs) were tested in adolescent depression and in several neurodevelopmental disorders with partial success. Anorexia nervosa (AN) is characterised by deficiencies in fatty food intake and frequent comorbidity, including depressive and cognitive symptoms. Thus supplementation with PUFAs may be beneficial in this group of patients. The aim of the study was to assess whether PUFAs as an add-on treatment is associated with better improvement of body mass index (BMI) and psychopathological symptoms than placebo in patients with AN. Method. 61 female adolescent inpatients with AN were randomly allocated to omega–3 PUFAs supplementation or placebo for 10 weeks. Patients also participated in the behavioural programme and eclectic psychotherapy (treatment as usual, TAU). At baseline and follow-up visits, patients’ BMI and psychopathology were assessed with Clinical Global Impression Scale (CGI), Patient Global Impression Scale (PGI), and Eating Attitude Test (EAT-26). Results. After 10 weeks, both groups showed improvement in all parameters. Improvement in CGI scores was observed greater in placebo vs. PUFA-s group (p = 0.015) while other differences were not statistically significant. Omega–3 PUFAs supplementation appears not to be effective as an add-on treatment in inpatient adolescent girls with anorexia nervosa. Conclusions. The results should be analysed with caution due to small sample size and heterogeneity in TAU. As the TAU turned out to be highly effective, additional therapeutic effect of PUFA might not be visible. Nevertheless, that does not explain the tendency for better improvement in the placebo group.


2013 ◽  
Author(s):  
Natalie Shepherd ◽  
Jager Cassandre De ◽  
Abe Kasonga ◽  
Sumari Marais ◽  
Yuko Tousen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document